This is the CDC's comment concerning antibiotic prophylaxis... and also on treatment.
Prophylactic antibiotics have been demonstrated to be quite effective in the prevention of TD. Controlled studies have shown that diarrhea attack rates are reduced from 40% to 4% by the use of antibiotics. The ideal antibiotic is one to which the pathogenic bacteria are sensitive, which has changed over the past few decades as resistance patterns have evolved (16). Agents such as TMP-SMX and doxycycline are no longer considered effective antimicrobial agents against enteric bacterial pathogens. The fluoroquinolones have been the most popular and effective antibiotics for the prophylaxis and treatment of bacterial TD pathogens, but increasing resistance to these agents, initially among Campylobacter species and now among other TD pathogens, may limit their benefit in the future. A newly approved nonabsorbable antibiotic, rifaximin, is being investigated for its potential use in TD prophylaxis (17). At this time prophylactic antibiotics should not be recommended for most travelers. In addition to affording no protection against nonbacterial pathogens, they may also give the traveler a false sense of security, leading to neglect of the food and water precautions that might protect against other enteric diseases. In addition, the use of antibiotics may be associated with allergic or adverse reactions in a certain percentage of travelers, an unnecessary occurrence, as early self-treatment with antibiotics for established TD is still quite effective.
Prophylactic antibiotics may be considered for short-term travelers who are high-risk hosts (such as those who are immunosuppressed) or are taking critical trips during which even a short bout of diarrhea could impact the purpose of their trip.
Treatment
Antibiotics are the principal element in the treatment of TD. Adjunctive agents used for symptomatic control may also be recommended.
ANTIBIOTICS
As bacterial causes of TD far outnumber other microbial etiologies, empiric treatment with an antibiotic directed at enteric bacterial pathogens remains the best therapy for TD (12). The benefit of treatment of TD with antibiotics has been proven in a number of studies. The effectiveness of a particular antimicrobial depends on the etiologic agent and its antibiotic sensitivity. Both as empiric therapy or for treatment of a specific bacterial pathogen, first-line antibiotics include those of the fluoroquinolone class, such as ciprofloxacin or levofloxacin. Increasing microbial resistance to the fluoroquinolones, especially among Campylobacter isolates, may limit their usefulness in some destinations such as Thailand and Nepal. An alternative to the fluoroquinolones in this situation is azithromycin. Rifaximin has been approved for the treatment of TD caused by noninvasive strains of E. coli (17).
The standard treatment regimens consist of 3 days of antibiotic, although when treatment is initiated promptly, shorter courses, including single-dose therapy, may reduce the duration of the illness to a few hours.
NONSPECIFIC AGENTS
Bismuth subsalicylate (BSS or Pepto-Bismol), taken as 1 oz of liquid or two chewable tablets every 30 minutes for eight doses, has been shown to decrease stool frequency and shorten the duration of illness in several placebo-controlled studies (14). This agent has both antisecretory and antimicrobial properties. BSS should be used with caution in travelers on aspirin therapy or anticoagulants or those who have renal insufficiency. In addition, BSS should be avoided in children with viral infections, such as varicella or influenza, because of the risk of Reye syndrome.
Other nonspecific agents, such as kaolin pectin, activated charcoal, and probiotics, have had a limited role in the treatment of TD.
ANTIMOTILITY AGENTS
Antimotility agents provide symptomatic relief and serve as useful adjuncts to antibiotic therapy in TD (12). Synthetic opiates, such as loperamide and diphenoxylate, can reduce bowel movement frequency and enable travelers to resume their activities while awaiting the effects of antibiotics. Loperamide appears to have antisecretory properties as well. These agents should not be used by travelers in diarrheal illness associated with high fever or blood in the stool, rather they should seek medical attention. Loperamide and diphenoxylate are not recommended for children <12 years of age.
ORAL REHYDRATION THERAPY
Fluid and electrolytes are lost in cases of TD, and replenishment is important, especially in young children or adults with chronic medical illness (18). In adult travelers who are otherwise healthy, severe dehydration resulting from TD is unusual unless vomiting is present. Nonetheless, replacement of fluid losses remains an important adjunct to other therapy. Travelers should remember to use only beverages that are sealed or carbonated. For more severe fluid loss, replacement is best accomplished with oral rehydration solutions (ORS), such as World Health Organization ORS solutions, which are widely available at stores and pharmacies in most developing countries. (See Table 4-20 for details.) ORS is prepared by adding one packet to the appropriate volume of boiled or treated water. Once prepared, solutions should be consumed or discarded within 12 hours (24 hours if refrigerated).
TREATMENT OF TD CAUSED BY PROTOZOA
The most common parasitic cause of TD is Giardia intestinalis, and treatment options include metronidazole, tinidazole, and nitazoxanide (10). Although cryptosporidiosis is usually a self-limited illness in immunocompetent persons, nitazox-anide can be considered as a treatment option. Cyclosporiasis is treated with TMP-SMX. Treatment of amebiasis is with metronidazole or tinidazole, followed by treatment with a luminal agent such as iodoquinol or paromomycin.
TREATMENT FOR CHILDREN
Children who accompany their parents on trips to high-risk destinations may be expected to have TD as well (19). There is no reason to withhold antibiotics from children who contract TD. In older children and teenagers, treatment recommendations for TD follow those for adults, with possible adjustments in dose of medication. Macrolides such as azithromycin are considered first-line antibiotic therapy in children, although some experts are using short-course fluoroquinolone therapy with caution for travelers younger than 18 years of age. Rifaximin is approved for use starting at age 12. Loperamide and diphenoxylate are not recommended for children younger than 12 years of age.
Infants and younger children are at higher risk for developing dehydration from TD, which is best prevented by the early use of ORS solutions. Breastfed infants should continue to nurse on demand, and bottle-fed infants should be offered full-strength lactose-free or -reduced formula. Older infants and children should continue their regular diets during the illness (see Chapter 8).